Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYong Mun

Discussion

Loading...

Member takes

Overview

Interim results show that subcutaneous mosunetuzumab achieves high response rates in elderly DLBCL patients, indicating safety for outpatient use.

Key Points

  • To evaluate the efficacy and safety of subcutaneous mosunetuzumab in elderly/unfit patients with untreated diffuse large B-cell lymphoma.
  • Open-label, multicenter, Phase II basket study
  • Enrolled elderly or unfit patients with previously untreated DLBCL
  • Administered mosunetuzumab subcutaneously over a fixed-duration
  • Measured progression-free survival and other efficacy endpoints
  • PFS rate at 12 months was 68.8%
  • ORR was 73.5% and CR rate was 59.2%
  • Median age of patients was 82.5 years
  • Most common adverse event was injection site reaction, occurring in 51% of patients

Cite This Study

Yong Mun (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd5https://doi.org/10.1182/blood-2025-62
View Full Paper
Ask AI
Bookmark
Share